Jubilant Life Sciences Ltd posted Rs.51 crore net profit for second quarter of this 2015-16 as against Rs.217 crore in the same period last year, registering 77 percent decline on standalone basis.
In a regulatory filing to the Bombay Stock Exchange (BSE), the pharma major said its income remained flat at Rs.746 crore in quarter under review as against Rs.751 crore in same period year ago on standalone basis.
On consolidated basis, the company turned into black, with Rs.116 crore net profit in Q2 from a net loss of Rs.94 crore year ago, while total income grew five percent to Rs.1,468 crore in Q2 from Rs.1,398 crore year ago.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app